I am an analyst at an Alternative Investment Manager and Commodity Trading Advisor located in Northern New Jersey.
I previously have worked at Societe Generale on the Securities Lending Trading Desk and at Merrill Lynch in the Credit Derivatives Department.
I graduated from Northeastern University in Boston, MA with a dual degree in Finance and Accounting and was a member of the Honors Program.
I currently invest in biotech stocks, mostly well ahead of ADCOM and PDUFA catalysts. I enjoy the satisfaction of knowing my equity is involved in the research and development of potential life-saving and life-improving technologies and medicines.
SNAPSHOT
Description: Hedge fund analyst.
Trading frequency: Daily
Hyman Beck & Company, Inc. Hyman Beck & Company, Inc. (HBC) is one of the world's most diversified alternative investment managers. Our Firm trades over seventy different products, ranging from global foreign exchange to precious metals and energy. Founded in 1991, HBC has created a long track record of managing assets for some of the ...More
world's most sophisticated institutional and high net worth investors.
HBC has demonstrated its ability to profit in bull and bear market cycles by providing investors with returns not correlated to long only benchmark indices. As our positions can be either long or short various markets, we can be indifferent to positive or negative market environments. We also enhance portfolio diversification by providing investors access to markets not typically represented in traditional stock and bond portfolios.
Blog
Currently, there are no blog details for jakerogers77.
BOOK
Currently, there are no book details for jakerogers77.
I previously have worked at Societe Generale on the Securities Lending Trading Desk and at Merrill Lynch in the Credit Derivatives Department.
I graduated from Northeastern University in Boston, MA with a dual degree in Finance and Accounting and was a member of the Honors Program.
I currently invest in biotech stocks, mostly well ahead of ADCOM and PDUFA catalysts. I enjoy the satisfaction of knowing my equity is involved in the research and development of potential life-saving and life-improving technologies and medicines.